Vir, GSK In Deal With NHS-Supported AGILE To Evaluate VIR-7832 In Early Treatment Of COVID-19

This post was originally published on this site

(RTTNews) – Vir Biotechnology, Inc. (VIR) and GlaxoSmithKline plc (GSK, GSK.L) announced Tuesday an agreement with the U.K.-based AGILE initiative to evaluate VIR-7832 in patients with mild to moderate COVID-19 in a Phase 1b/2a clinical trial.

The trial is due to begin in the first quarter of 2021.

VIR-7832 is a neutralizing COVID-19 antibody…

Bastion Balance Seoul, Korea.